Drug resistance and plasmid profile of uropathogenic Escherichia coli among urinary tract infection patients in Addis Abeba

Dadi, Belayneh Regasa; Abebe, Tamrat; Zhang, Lixin; Mihret, Adane; Abebe, Workeabeba; Amogne, Wondwossen

doi:10.3855/jidc.9916

Cited by 16 publications

(8 citation statements)

References 22 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study high prevalence of drug resistance to ceftazidime (84%), ceftriaxone (80.5%), and cefotaxime (66%) was observed [52]. Resistance to ceftriaxone was observed in 80.5% of UPEC isolates, which is comparable to studies conducted in Nigeria 86% [13], India 81.8% [53] and China 84.8% [30], but higher than studies conducted in Nigeria 23.3% [54] and Mexico 10.2% [21].…”

Section: Discussionsupporting

confidence: 63%

Distribution of virulence genes and phylogenetics of uropathogenic Escherichia coli among urinary tract infection patients in Addis Ababa, Ethiopia

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: Urinary tract infection (UTI) is a common cause of morbidity worldwide. Uropathogenic Escherichia coli (UPEC) bacteria are the major cause of urinary tract infections. UPEC strains derive from different phylogenetic groups and possess an arsenal of virulence factors that contribute to their ability to overcome different defense mechanisms and cause disease. The objective of this study was to identify phylogroup and virulence genes of UPEC among urinary tract infection patients. Methods: A cross sectional study was conducted from January 1, 2017 to October 9, 2017. E. coli bacteria were isolated from UTI patients using culture and conventional biochemical tests. Identification of phylogroup and genes that encodes for virulence factors was done using multiplex polymerase chain reaction (PCR). Data was processed and analyzed with SPSS version16.0 and Epi-info version 3.4.1 software. Results: The most common urologic clinical manifestation combinations in this study were dysuria, urine urgency and urgency incontinence. The frequent UPEC virulence gene identified was fimH 164 (82%), followed by aer 109 (54.5%), hly 103 (51.5%), pap 59 (29.5%), cnf 58 (29%), sfa 50 (25%) and afa 24 (12%).There was significant association between pap gene and urine urgency (p-0.016); sfa and dysuria and urine urgency (p-0.019 and p-0.043 respectively); hly and suprapubic pain (p-0.002); aer and suprapubic pain, flank pain and fever (p-0.017, p-0.040, p-0.029 respectively). Majority of E. coli isolates were phylogroup B2 60(30%) followed by D 55(27.5%), B1 48(24%) and A 37(18.5%). There was significant association between E. coli phylogroup B2 and three virulence genes namely afa, pap, and sfa (p-0.014, p-0.002, p-0.004 respectively). Conclusion: In this study the most frequent E. coli virulence gene was fimH, followed by aer, hly, pap, cnf, sfa and afa respectively. There was significant association between E. coli virulence genes and clinical symptoms of UTI. The phylogenetic analysis indicates majority of uropathogenic E. coli isolates were phylogroup B2 followed by phylogroup D. Phylogroup B2 carries more virulence genes. Hence, targeting major UPEC phylogroup and virulence genes for potential vaccine candidates is essential for better management of UTI and further research has to be conducted in this area.

show abstract

Section: Discussionsupporting

confidence: 63%

Distribution of virulence genes and phylogenetics of uropathogenic Escherichia coli among urinary tract infection patients in Addis Ababa, Ethiopia

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…The activity of TMP-SMZ against UPEC in other regions of the world was significantly lower as the frequencies of TMP-SMZ resistant UPEC isolates ranged from 72.7% in Mexico to 82% in Pakistan (Ali et al 2016;Ramírez-Castillo et al 2018). High resistance to TMP-SMZ was also observed in Iran (54%), Ethiopia (68.5%), Mongolia (70.9%), and Jordan (73,1%) (Raeispour and Ranjbar 2016;Munkhdelger et al 2017;Regasa Dadi et al 2018;Shakhatreh et al 2018). These results indicate that in many countries TMP-SMZ should not be used in empiric UTI therapy due to the high frequency of UPEC resistant to this antimicrobial.…”

Section: Resistance To Trimethoprim-sulfamethoxazolementioning

confidence: 99%

“…(Abernethy et al 2017). Resistance to ciprofloxacin was significantly higher in developing countries (Ethiopia -85.5%, Nepal -64.6%, Pakistan -60.8%, Mongolia -58.1%, Jordan -55.5%) (Ali et al 2016, Khatri et al 2017Munkhdelger et al 2017;Regasa Dadi et al 2018;Shakhatreh et al 2018) than in developed countries (USA -5.1%, Germany -10.5%, Switzerland -17.4%, France -24.8%) (Lavigne et al 2016;Erb et al 2018;Hitzenbichler et al 2018;Yamaji et al 2018). The study conducted in Switzerland showed also that patient age over 65 years was associated with higher E. coli resistance to ciprofloxacin (Erb et al 2018).…”

mentioning

confidence: 98%

Antibiotic Resistance Among Uropathogenic Escherichia coli

Kot

2019

Polish Journal of Microbiology

190

131

View full text Add to dashboard Cite

Urinary tract infections (UTIs) belong to the most common community-acquired and nosocomial infections. A main etiological factor of UTIs is uropathogenic Escherichia coli (UPEC). This review describes the current state of knowledge on the resistance of UPEC to antibiotics recommended for the treatment of UTIs based on the available literature data. Nitrofurantoin and fosfomycin are recommended as first-line therapy in the treatment of uncomplicated cystitis, and the resistance to these antimicrobial agents remains low between UPEC. Recently, in many countries, the increasing resistance is observed to trimethoprim-sulfamethoxazole, which is widely used as the first-line antimicrobial in the treatment of uncomplicated UTIs. In European countries, the resistance of UPEC to this antimicrobial agent ranges from 14.6% to 60%. The widespread use of fluoroquinolones (FQs), especially ciprofloxacin, in the outpatients is the cause of a continuous increase in resistance to these drugs. The resistance of UPEC to FQs is significantly higher in developing countries (55.5–85.5%) than in developed countries (5.1–32.0%). Amoxicillin-clavulanic acid is recommended as first line-therapy for pyelonephritis or complicated UTI. Resistance rates of UPEC to amoxicillin-clavulanic acid are regionally variable. In European countries the level of resistance to this antimicrobial ranges from 5.3% (Germany) to 37.6% (France). Increasing rates of UPEC resistance to antimicrobials indicate that careful monitoring of their use for UTI treatment is necessary.

show abstract

“…For instance, vancomycin and antistaphylococcal penicillin are used empirically to inhibit Staphylococcus aureus bacteremia; vancomycin is the rst choice for MRSA treatment [15][16][17]. Fosfomycin-trometamol and nitrofurantoin have been recommended as rst-line antibiotics for frequently uncomplicated cystitis; uoroquinolones are the oral rst-line treatment for uncomplicated pyelonephritis as E.coli is the leading uropathogen of uncomplicated urinary tract infections [18][19][20].…”

Section: Discussionmentioning

confidence: 99%

Antimicrobial Activity Study of Chinese Medicine Madeng’ai

Tang¹,

Zhao²,

Zhang³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Due to the overuse of antibiotics, many multidrug-resistant bacteria have emerged, which brings huge challenges to the clinical treatment of bacterial infections. New products for anti-infection are necessary. Methods Madeng’ai powder was added with Milli-Q water or LB culture and autoclaved to prepare medicine suspension at different concentration. Bacteria were cultured in LB with different concentration of Madeng’ai. and swab on LB agar plates to get minimal inhibitory concentration (MIC) of Madeng’ai. Mice back was cut to make wound and MRSA/PAE suspension was injected in the wound area. Then swab with Madeng’ai extracts. Bacteria growth of infected secretions was checked on LB agar, and Hematoxylin and eosin (H&E) staining was performed for Histological analysis of skin tissues infected with bacteria after Madeng’ai and PBS (control) treatment. Results Madeng’ai could widely inhibit E.faecalis, Pseudomonas aeruginosa (PAE), Klebsiella pneumoniae (K.pneumoniae) and Acinetobacter baumannii (A.baumannii) at concentration of 4.0 mg/ml. The mice model also showed that Madeng’ai had imposed restrictions on MRSA and PAE growth in vivo. Conclusion Here, we report that a new Chinese medicine Madeng’ai has antimicrobial activity functions in vitro and in vivo. These data briefly showed that Madeng’ai functioned on antimicrobial and provided a new consideration for an antibiosis product.

show abstract

Drug resistance and plasmid profile of uropathogenic Escherichia coli among urinary tract infection patients in Addis Abeba

Cited by 16 publications

References 22 publications

Distribution of virulence genes and phylogenetics of uropathogenic Escherichia coli among urinary tract infection patients in Addis Ababa, Ethiopia

Distribution of virulence genes and phylogenetics of uropathogenic Escherichia coli among urinary tract infection patients in Addis Ababa, Ethiopia

Antibiotic Resistance Among Uropathogenic Escherichia coli

Antimicrobial Activity Study of Chinese Medicine Madeng’ai

Contact Info

Product

Resources

About